Medicine & Life Sciences
atezolizumab
100%
Pharmacokinetics
90%
Itraconazole
42%
Rheumatoid Arthritis
36%
Survival
34%
Metabolomics
34%
Healthy Volunteers
32%
Patient Reported Outcome Measures
29%
Non-Small Cell Lung Carcinoma
28%
Pharmaceutical Preparations
27%
Population
26%
Antirheumatic Agents
26%
tocilizumab
26%
Gastrointestinal Transit
26%
Immunotherapy
24%
Oxycodone
23%
Clinical Trials
23%
Breast Neoplasms
22%
Delayed-Action Preparations
21%
Tablets
20%
Machine Learning
20%
hydroxyitraconazole
20%
Eudragit E PO
18%
Meta-Analysis
16%
Therapeutics
16%
Proteomics
16%
5-(4-ethylpiperazin-1-ylmethyl)pyridin-2-yl)-(5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzimidazol-5-yl)pyrimidin-2-yl)amine
15%
Neoplasms
15%
C-Reactive Protein
15%
Progression-Free Survival
14%
Glioblastoma
14%
Febuxostat
14%
Lung Neoplasms
13%
Obesity
13%
Food
13%
Interleukin-1 Receptor-Associated Kinases
13%
Carcinoma
13%
methylmethacrylate-methacrylic acid copolymer
12%
Biological Availability
12%
Treatment-Resistant Depressive Disorder
11%
Proton Pump Inhibitors
11%
High Pressure Liquid Chromatography
11%
Coronavirus
11%
Sorafenib
10%
human ERBB2 protein
10%
Omeprazole
10%
Bevacizumab
10%
Gout
10%
Body Mass Index
10%
Clarithromycin
10%
Chemical Compounds
Drug
41%
Pharmacokinetics
32%
Oxycodone
29%
Metabolite
21%
Metabolic
17%
Sorafenib
13%
Twice Daily
13%
Clarithromycin
13%
Time
13%
Itraconazole
13%
Simvastatin
12%
Dissolution
12%
Etoposide
12%
Liquid
12%
pH Value
12%
Bioavailability
10%
Paclitaxel
10%
5-Fluorouracil
10%
Food
10%
Safety
7%
Application
6%
Dose
6%
Time Schedule of Dosing
5%
Chloroform
5%
Ionization
5%
Heterogeneity
5%
Methanol
5%